# First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

> **NCT05648006** · PHASE2 · TERMINATED · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Advanced Colorectal Carcinoma

## Interventions

- **BIOLOGICAL:** OH2
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05648006
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-17
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-04-15
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Strategy adjustment
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05648006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05648006, "First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05648006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*